Ensemble Therapeutics is focused on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. We are aggressively applying our drug discovery experience and proprietary drug discovery platform to develop novel small molecule therapies against well-validated, but challenging disease targets that are not adequately treated by conventional small molecules or antibodies.
We are building a differentiated pipeline of promising therapies primarily focused on indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) immune checkpoint inhibitors and deubiquitinase (DUB) antagonists. Our growing pipeline includes macrocycles and other creative small molecule solutions that expands the boundaries of traditional therapeutics to impact important disease targets inside or outside cells.
Our DNA-encoded chemistry platform gives the company unmatched capabilities to successfully generate and screen millions of compounds. With our discovery platform, we go beyond the constraints of conventional small molecule drug discovery by identifying and advancing novel structures beyond the traditional ‘Rule of 5’ that possess drug like properties.
Our lead oncology program is focused on the immune checkpoint target IDO, which is implicated in a variety of cancers including those of prostate, colorectal, pancreatic, cervical, gastric, ovarian, and lung. We also have a number of other preclinical development programs in oncology.
Ensemble was founded in 2004 by renowned Harvard Professor David R. Liu, Ph.D., and is backed by a blue-chip investor syndicate.